Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$101.7MBeat by $39.4M
EPS$3.28Beat by $1.31
Revenue estimate$62.3M
EPS estimate$1.97

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$55.3M
EPS estimate$0.13

Financials

Q2 2025

Income statement

See full
Revenue$101.7M+176%
Gross profit$97.2M+186%
Operating income$61.1M+13,570%
Net income$59.6M+5,888%
EPS (diluted)$3.28+5,567%

Balance sheet

See full
Cash & equivalents$53.4M+48.1%
Total debt$1.2M+92.6%
Total equity$81.9M+374%
Total assets$206.7M+61.0%

Cash flow

See full
Operating cash flow$30.5M+10,012%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$334.21M+132%
Enterprise value$282.04M+159%
P/E3.4×—
P/S1.2×+0.1×

Profitability

See full
Gross margin91.5%-0.9pp
Operating margin39%+33.1pp
Net margin36.5%+29.5pp

Returns & leverage

See full
Debt / equity0×—
Current ratio2×+0.4×

Segments

By product

See full
Gross product sales$79.7M+62.7%
Delivery of drug supplies, royalties and others$2.8M-18.7%
Discounts and allowances-$20.7M-33.6%

Versus estimates

Revenue

Q1 2026$58.8MMiss by $3.6MQ4 2025$69.8MBeat by $1.1MQ3 2025$69.5MBeat by $1.0M
Q2 2025$101.7MBeat by $39.4M
Q1 2025$53.3MBeat by $5.0MQ4 2024$57.6MIn line

Diluted EPS

Q1 2026$0.44Miss by $0.30Q4 2025$1.14Miss by $0.19Q3 2025$1.46Beat by $0.53
Q2 2025$3.28Beat by $1.31
Q1 2025$0.63Beat by $0.49Q4 2024$0.80Beat by $0.50

Ask the moment Rigel Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rigel Pharmaceuticals report Q2 2025 earnings?
Rigel Pharmaceuticals (RIGL) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Rigel Pharmaceuticals's Q2 2025 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $101.7M and eps of $3.28 for Q2 2025.
Did Rigel Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $62.3M by $39.4M. EPS beat the consensus estimate of $1.97 by $1.31.
How did Rigel Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 176.0% from $36.8M a year earlier.
Where can I find Rigel Pharmaceuticals's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-010281) directly on SEC EDGAR. The filing index links above go to sec.gov.